ArticleOncoTargets and therapy2016
MiR-502-3P suppresses cell proliferation, migration, and invasion in hepatocellular carcinoma by targeting SET.
Article in OncoTargets and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Potential of hsa-miR200a-3p and hsa-miR502-3p as blood-based biomarker for Alzheimer's disease.Molecular biology reports · 2022Article
- Circular RNA circPDSS1 promotes osteosarcoma progression by sponging miR-502-3p and miR-4436a.Anti-cancer drugs · 2022Article
- MicroRNA Alterations Induced in Human Skin by Diesel Fumes, Ozone, and UV Radiation.Journal of personalized medicine · 2022Article
- The Key Role of microRNAs in Initiation and Progression of Hepatocellular Carcinoma.Frontiers in oncology · 2022Review
- MicroRNA‑502‑3p promotesMolecular medicine reports · 2021Article
- MicroRNA signatures associated with lymph node metastasis in intramucosal gastric cancer.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021Article
- miR-502-5p affects gastric cancer progression by targeting PD-L1.Cancer cell international · 2020Article
- Plasma extracellular vesicle microRNAs for pulmonary ground-glass nodules.Journal of extracellular vesicles · 2019Article
- Detecting Differentially Variable MicroRNAs via Model-Based Clustering.International journal of genomics · 2018Article
- Diagnostic value of strand-specific miRNA-101-3p and miRNA-101-5p for hepatocellular carcinoma and a bioinformatic analysis of their possible mechanism of action.FEBS open bio · 2018Article
- Profile of 6 microRNA in blood plasma distinguish early stage Alzheimer's disease patients from non-demented subjects.Oncotarget · 2017Article
- A Novel miRNA-Based Model Can Predict the Prognosis of Clear Cell Renal Cell Carcinoma.Technology in cancer research & treatmentArticle
Corrections and comments
- Retraction · 2021-05-18Duplication of/in Image · Error in Image · Original Data and/or Images not Provided and/or not Available · Paper Mill · · see also: https://pubpeer.com/publications/5A7ED3A2B9AF8E431CEF7748C5A154
- Retracted
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimIncreasing evidences show that microRNAs are engaged in hepatocellular carcinoma (HCC). The aim of this study was to investigate the role of miR-502-3P in HCC and to identify its underlying mechanism.
methodsThe expression levels of miR-502-3P were assessed in multiple HCC cell lines and in liver tissues of patients with HCC. We further examined the effects of miR-502-3P on malignant behavior of HCC. The molecular target of miR-502-3P was identified using a computer algorithm and confirmed experimentally.
resultsDownregulation of miR-502-3P was found in both HCC cell lines and human samples. Overexpression of miR-502-3P dramatically inhibits HCC proliferation, metastasis, invasion, and cell adhesion. We further verify the SET as a novel and direct target of miR-502-3P in HCCs.
conclusionTaken together, overexpression of miR-502-3P or downregulation of SET may prove beneficial as a therapeutic strategy for HCC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.